Clinical pharmacokinetics of nebivolol: a systematic review

References

• Baratam SR, Ramanamma C, Chowdary K. 2016. Development of self emulsifying drug delivery system of nebivolol for the improvement of solubility and dissolution. 5.
   Google Scholar
• Bollam V, Dodle J, Anisetti R. 2013. Effect of lansoprazole on pharmacokinetics of nebivolol in hypertensive patients. Ann Biol Res. 4(10):6–10.
   Google Scholar
• Briciu C, Neag M, Muntean D, Bocsan C, Buzoianu A, Antonescu O, Gheldiu AM, Achim M, Popa A, Vlase L. 2015. Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. Clujul Med. 88(2):208–213. doi: 10.15386/cjmed-395.
   PubMedGoogle Scholar
• Briciu C, Neag M, Muntean D, Vlase L, Bocsan C, Buzoianu A, Gheldiu A, Achim M, Popa A. 2014. A pharmacokinetic drug interaction study between nebivolol and duloxetine. Exp Clin Cardiol. 20(1):1374–1379.
   Google Scholar
• Briciu C, Neag M, Muntean D, Vlase L, Bocsan C, Buzoianu A, Gheldiu AM, Achim M, Popa A. 2014. A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. J Clin Pharm Ther. 39(5):535–540. doi: 10.1111/jcpt.12180.
   PubMed Web of Science ®Google Scholar
• Chen CL, Desai-Krieger D, Ortiz S, Kerolous M, Wright HM, Ghahramani P. 2015. A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State. Am J Ther. 22(5):e130-140–e140. doi: 10.1097/MJT.0000000000000247.
   Web of Science ®Google Scholar
• Cheng JWM. 2009. Nebivolol: a third-generation β-blocker for hypertension. Clin Ther. 31(3):447–462. doi: 10.1016/j.clinthera.2009.03.007.
   PubMed Web of Science ®Google Scholar
• Cheymol G, Woestenborghs R, Snoeck E, Ianucci R, Le Moing JP, Naditch L, Levron JC, Poirier JM. 1997. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol. 51(6):493–498. doi: 10.1007/s002280050237.
   PubMed Web of Science ®Google Scholar
• Fongemie J, Felix-Getzik E. 2015. A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs. 75(12):1349–1371. doi: 10.1007/s40265-015-0435-5.
   PubMed Web of Science ®Google Scholar
• Gheldiu AM, Popa A, Neag M, Muntean D, Bocsan C, Buzoianu A, Vlase L, Tomuta I, Briciu C. 2016. Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. Pharmacology. 98(3-4):190–198. doi: 10.1159/000447266.
   PubMed Web of Science ®Google Scholar
• Gheldiu AM, Vlase L, Popa A, Briciu C, Muntean D, Bocsan C, Buzoianu A, Achim M, Tomuta I, Todor I, et al. 2017. Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. J Pharm Pharm Sci. 20:68–80. doi: 10.18433/J3B61H.
   PubMed Web of Science ®Google Scholar
• Gray CL, Ndefo UA. 2008. Nebivolol: a new antihypertensive agent. Am J Health Syst Pharm. 65(12):1125–1133. doi: 10.2146/ajhp070459.
   PubMed Web of Science ®Google Scholar
• Guo L, Wang S, Wan Z, Ni S, Xu B, Zhao X, Liu L. 2020. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects. J Clin Pharm Ther. 45(4):632–637. doi: 10.1111/jcpt.13155.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. 2011. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343(oct18 2):d5928–d5928. doi: 10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). 2022. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022; [accessed April 4, 2023]. www.training.cochrane.org/handbook. Chichester, UK: John Wiley & Sons, Ltd.
   Google Scholar
• Hilas O, Ezzo D. 2009. Nebivolol (bystolic), a novel Beta blocker for hypertension. P t. 34(4):188–192.
   PubMedGoogle Scholar
• Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. 1996. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol. 51(3-4):259–264. doi: 10.1007/s002280050194.
   PubMed Web of Science ®Google Scholar
• Kamali F, Howes A, Thomas SH, Ford GA, Snoeck E. 1997. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol. 43(2):201–204. doi: 10.1046/j.1365-2125.1997.54212.x.
   PubMed Web of Science ®Google Scholar
• Kumar Saini A, Wal P, Verma M, Chandra S, Singh A, Yadav S, Bansode H, Nischaya K, Saraswat N. 2018. Nebivolol: an Appealing, Awaited and Nitric Oxide Potentiator Drug for the Treatment of Heart Failure. JYP. 10(2):149–154. doi: 10.5530/jyp.2018.10.34.
   Web of Science ®Google Scholar
• Lindamood C, Ortiz S, Shaw A, Rackley R, Gorski JC. 2011. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug‐drug interaction studies. J Clin Pharmacol. 51(4):575–585. doi: 10.1177/0091270010370846.
   PubMed Web of Science ®Google Scholar
• Long HA, French DP, Brooks JM. 2020. Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Res Methods Med Health Sci. 1(1):31–42. doi: 10.1177/2632084320947559.
   Google Scholar
• Luo X, Lei Y, He L, Liu W, Li M, Ran L, Yu M, Guo X, Yu P, Liu Z, et al. 2015. No influence of CYP2D6*10 genotype and phenotype on the pharmacokinetics of nebivolol in healthy Chinese subjects. J Clin Pharm Ther. 40(5):561–565. doi: 10.1111/jcpt.12310.
   PubMed Web of Science ®Google Scholar
• Mangrella M, Rossi F, Fici F, Rossi F. 1998. Pharmacology of nebivolol. Pharmacol Res. 38(6):419–431. doi: 10.1006/phrs.1998.0387.
   PubMed Web of Science ®Google Scholar
• Marketou M, Gupta Y, Jain S, Vardas P. 2017. Differential metabolic effects of beta-blockers: an updated systematic review of nebivolol. Curr Hypertens Rep. 19(3):22. doi: 10.1007/s11906-017-0716-3.
   PubMed Web of Science ®Google Scholar
• Marques L, Costa B, Vale N. 2022. New data for nebivolol after in silico PK study: focus on young patients and dosage regimen. Pharmaceutics. 14(9):1911. doi: 10.3390/pharmaceutics14091911.
   PubMed Web of Science ®Google Scholar
• McNeely W, Goa KL. 1999. Nebivolol in the management of essential hypertension. Drugs. 57(4):633–651. doi: 10.2165/00003495-199957040-00011.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 151(4):264–269, W64. doi: 10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Münzel T, Gori T. 2009. Nebivolol. J Am Coll Cardiol. 54(16):1491–1499. doi: 10.1016/j.jacc.2009.05.066.
   PubMed Web of Science ®Google Scholar
• Olawi N, Krüger M, Grimm D, Infanger M, Wehland M. 2019. Nebivolol in the treatment of arterial hypertension. Basic Clin Pharmacol Toxicol. 125(3):189–201. doi: 10.1111/bcpt.13248.
   PubMed Web of Science ®Google Scholar
• Nebivolol hydrochloride. 2023. PubChem. [Internet]. Bethesda (MD): national Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 9933004; [accessed 2023 Mar. 30]. https://pubchem.ncbi.nlm.nih.gov/compound/Nebivolol-hydrochloride.
   Google Scholar
• Neves DV, Lanchote VL, Moysés Neto M, Cardeal da Costa JA, Vieira CP, Coelho EB. 2016. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. Br J Clin Pharmacol. 82(1):83–91. doi: 10.1111/bcp.12917.
   PubMed Web of Science ®Google Scholar
• Neves DV, Vieira CP, Coelho EB, Marques MP, Lanchote VL. 2013. Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 940:47–52. doi: 10.1016/j.jchromb.2013.09.031.
   PubMed Web of Science ®Google Scholar
• Priyadarshni S, Curry BH. 2022. Nebivolol. StatPearls Publishing, Treasure Island (FL); [updated 2022; accessed]. https://www.ncbi.nlm.nih.gov/books/NBK551582.
   Google Scholar
• Rubin K, Sullivan D, Sadhasivam S. 2009. Are peripheral and neuraxial blocks with ultrasound guidance more effective and safe in children? Paediatr Anaesth. 19(2):92–96. doi: 10.1111/j.1460-9592.2008.02918.x.
   PubMed Web of Science ®Google Scholar
• Sahana G, Sarala N, Kumar T. 2011. Nebivolol-pharmacological aspects. Int J Biol Med Res. 2(2):577–580.
   Google Scholar
• Seleme VB, Marques GL, Mendes AEM, Rotta I, Pereira M, Júnior EL, da Cunha CLP. 2021. Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: a Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 21(2):165–180. doi: 10.1007/s40256-020-00422-0.
   PubMed Web of Science ®Google Scholar
• Selvan PS, Gowda KV, Mandal U, Solomon WD, Pal TK. 2007. Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 858(1-2):143–150. doi: 10.1016/j.jchromb.2007.08.016.
   PubMed Web of Science ®Google Scholar
• Soliman ABE, Pawluk SA, Wilby KJ, Rachid O. 2022. The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies. Int J Clin Pharm. 44(4):894–903. doi: 10.1007/s11096-022-01390-y.
   PubMed Web of Science ®Google Scholar
• Sule SS, Frishman W. 2006. Nebivolol: new therapy update. Cardiol Rev. 14(5):259–264. doi: 10.1097/01.crd.0000223651.03023.8e.
   PubMedGoogle Scholar
• Sullo MG, Perri D, Sibilio M, Rafaniello C, Fucile A, Rossi F, Capuano A. 2015. Hypoglycemia, polycythemia and hyponatremia in a newborn exposed to nebivolol during pregnancy. J Pharmacol Pharmacother. 6(1):45–48. doi: 10.4103/0976-500X.149148.
   PubMedGoogle Scholar
• Toblli JE, DiGennaro F, Giani JF, Dominici FP. 2012. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag. 8:151–160. doi: 10.2147/VHRM.S20669.
   PubMedGoogle Scholar
• Venkateswarlu B, Jayaprakash D, Anisetti R, Narsaiah N, Reddy MR. 2013. Effect of cefixime on pharmacokinetics of nebivolol in hypertensive patients. Int J Pharm Sci Res. 4(11):4362.
   Google Scholar
• Vespasiano CF, Laurito TL, Iwamoto RD, Moreno RA, Mendes GD, De Nucci G. 2017. Bioequivalence study between a fixed-dose single-pill formulation of nebivolol plus hydrochlorothiazide and separate formulations in healthy subjects using high-performance liquid chromatography coupled to tandem mass spectrometry. Biomed Chromatogr. 31(5). doi: 10.1002/bmc.3884.
   PubMed Web of Science ®Google Scholar
• Vieira CP, Neves DV, Cesarino EJ, Rocha A, Poirier S, Lanchote VL. 2017. An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. J Pharm Biomed Anal. 144:25–30. doi: 10.1016/j.jpba.2017.01.054.
   PubMed Web of Science ®Google Scholar
• Wojciechowski D, Papademetriou V. 2008. Beta-blockers in the management of hypertension: focus on nebivolol. Expert Rev Cardiovasc Ther. 6(4):471–479. doi: 10.1586/14779072.6.4.471.
   PubMedGoogle Scholar